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Abstract: Cisplatin is a chemotherapeutic agent widely used for multiple indications. Unfortunately,
in a substantial set of patients treated with cisplatin, dose-limiting acute kidney injury (AKI) occurs.
Here, we assessed the association of 3 catechol-O-methyltransferase (COMT) single nucleotide
polymorphisms (SNPs) with increased cisplatin-induced nephrotoxicity. In total, 551 patients were
genotyped for the 1947 G>A (Val158Met, rs4680), c.615 + 310 C>T (rs4646316), and c.616–367 C>T
(rs9332377) polymorphisms. Associations between these variants and AKI grade ≥3 were studied.
The presence of a homozygous variant of c.616-367C>T was associated with a decreased occurrence
of AKI grade 3 toxicity (p = 0.014, odds ratio (OR) 0.201, 95% confidence interval (CI) (0.047–0.861)).
However, we could not exclude the role of dehydration as a potential cause of AKI in 25 of the
27 patients with AKI grade 3, which potentially affected the results substantially. As a result of the
low incidence of AKI grade 3 in this dataset, the lack of patients with a COMT variant, and the high
number of patients with dehydration, the association between COMT variants and AKI does not
seem clinically relevant.
Keywords: cisplatin; acute kidney injury; COMT; nephrotoxicity; SNP
1. Introduction
Cisplatin is a widely used cytostatic agent that interferes with DNA replication by binding within
(and between) DNA strands resulting in the inhibition of protein synthesis and DNA replication. It is
approved for the treatment of many types of cancer such as testicular seminoma, non-small cell lung
cancer, and head and neck cancer [1]. Common toxicities associated with cisplatin treatment include
nephrotoxicity, ototoxicity, and leukopenia, of which nephrotoxicity is the main cause of dose reduction
or even termination of systemic therapy. Treatment-related acute kidney injury (AKI) occurs in 20–30%
of cisplatin-treated patients and is dose-dependent [2].
In a recently published case report, the potential role of catechol-O-methyltransferase (COMT) on
cisplatin-induced nephrotoxicity was suggested [3]. Single nucleotide polymorphisms (SNPs) in five
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candidate genes, of which two are SNPs in COMT, were genotyped in a young woman who developed
severe irreversible cisplatin-induced nephropathy. Both COMT polymorphisms were already known
to be associated with cisplatin induced ototoxicity [4,5] and were homozygous polymorphic in this
patient (c.615 + 310C>T (rs4646316) and c.616-367C>T (rs9332377)) [3]. As COMT is an enzyme that
inactivates catecholamines by transferring a methyl group of S-adenosyl methionine (SAM) into a
catecholamine neurotransmitter (such as dopamine, epinephrine, and norepinephrine), the authors
hypothesized that the mechanism of cisplatin-induced nephrotoxicity could be mediated by increased
SAM concentrations. This theory is supported by data from a mouse model study where cisplatin
toxicity was 3- to 6-fold increased when SAM and cisplatin were administered concomitantly, compared
to cisplatin administration alone [6]. The association between these two COMT polymorphisms and
cisplatin-induced nephrotoxicity has not been validated in further clinical research.
Another polymorphism in the COMT gene, the COMT 1947G>A (rs4680), is also known to affect
COMT function [7]. This SNP is associated with response to other drugs [8–11], but has not been tested
yet for the association with cisplatin-induced AKI.
Here, we studied the association between these three COMT polymorphisms and cisplatin-induced
nephrotoxicity in a large cohort of cancer patients in order to assess the clinical relevance of these SNPs
and their potential use as predictor in this context.
2. Methods
2.1. Study Design
Patients treated with cisplatin at the Erasmus MC Cancer Institute according to standard of care
between January 2004 and April 2019 and who provided informed consent to prospectively perform
DNA genotyping in their blood samples (Erasmus MC institutional review board study number MEC
02.1002) were included in this genetic association study. Patients treated with cisplatin and pemetrexed
in the PERSONAL (PEmetrexed and biomaRkerS: an observatiONAL) study were also included
in this analysis [12]. All patients were advised to drink two liters of water a day during cisplatin
treatment and four liters of glucose/NaCl/KCl/MgSO4 solution was administered intravenously in
24 h on the day of cisplatin administration. The most recent plasma creatinine concentrations within
two weeks prior to the first cisplatin administration were used as a baseline value. The highest
plasma creatinine concentration within the period of first cisplatin administration until three weeks
after the second 3-weekly administration was used for statistical analysis. Patients were excluded if
baseline or on-treatment creatinine concentrations were not available or if the cisplatin dosage was not
clearly recorded.
2.2. Classification of Endpoints and Adverse Events
AKI was graded according to the Common Terminology Criteria of Adverse Events (CTCAE)
version 4.03 (Table 1) [13]. AKI grade 3 or higher was interpreted as ‘severe AKI’, and was, therefore,
the primary outcome in this study.
Of patients with AKI grade 3 or higher, the patient files were studied for potential confounders,
such as dehydration and renal and post-renal pathology and recovery. When the plasma creatinine
concentrations of these patients did not return to baseline +20 µmol/L in 2 years after cisplatin
administration, this was classified as irreversible cisplatin-induced nephrotoxicity.
2.3. DNA Isolation and TaqMan®Genotyping
DNA was isolated using the MagNA Pure 96 Instrument (Roche Diagnostics GmbH, Rotkreuz,
Switzerland), from 500 µL of the whole-blood specimens using the MagNA Pure 96 DNA and Viral
Large Volume Kit (Roche Diagnostics GmbH, Rotkreuz, Switzerland). The selected COMT SNPs were
genotyped using predesigned Drug Metabolism Enzymes TaqMan®allelic discrimination assays on the
Life Technologies TaqMan®7500 system (Applied Biosystems, Life Technologies Europe BV, Bleijswijk,
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The Netherlands). Assay IDs are listed in Table 2. Each assay contains assay-specific primers and
allele-specific minor groove binding probes labelled with VIC™ and FAM™ fluorescent dyes. Using
these assays, TaqMan®GTXpress Master Mix and 20 µg genomic DNA, the polymerase chain reactions
were performed in a reaction volume of 12 µL. The thermal profile of the TaqMan®qPCR reaction
consisted of 40 cycles of denaturation (95 ◦C for 20 s), annealing (92 ◦C for 3 s), and extension (60 ◦C for
30 s). Genotypes were determined by measuring allele-specific fluorescence using the TaqMan®7500
software v2.3 for allelic discrimination.
Table 1. Definition of Common Terminology Criteria of Adverse Events (CTCAE) and Kidney Disease:
Improving Global Outcomes (KDIGO) grading of acute kidney disease (AKI) in adults [13,14].
CTCAE KDIGO
Grade Serum creatinine Stage Serum creatinine Urine output
1 1.5–2.0 × baseline; OR≥0.3 mg/dL (26.5 µmol/L) increase 1
1.5–1.9 × baseline; OR
≥0.3 mg/dL (26.5 µmol/L <0.5 mL/kg/h for 6–12 h
2 2.0–3.0 × baseline 2 2.0–2.9 × baseline <0.5 mL/kg/h for ≥12 h
3
>3.0 × baseline; OR
> 4.0 mg/dL (353.6 µmol/L) increase;
OR
Hospitalization indicated
3
3.0 × baseline; OR
≥ 4.0 mg/dL (353.6 µmol/L)
increase; OR
Initiation of renal
replacement therapy
<0.3 mL/kg/h for ≥24 h;
OR
anuria for ≥12 h
4 Life-threatening consequences; ORDialysis indicated
5 Death
Table 2. Details and distributions of the studied single nucleotide polymorphisms (SNPs).
Gene rs number Variant Assay ID WT HT HM MAF HW
COMT
rs4646316 c.615 + 310C>T C__29193982_10 316 204 31 24% 0.80
rs9332377 c.616-367C>T C__29614343_10 400 140 11 15% 0.76
rs4680 c.472G>A (Val158Met) C__25746809_50 117 282 152 53% 0.51
WT, wildtype; HT, heterozygous variant; HM, homozygous variant; MAF, minor allele frequency; HW,
Hardy-Weinberg P value
2.4. Statistical Analysis
Distribution of genotypes was tested for Hardy Weinberg equilibrium; if p < 0.05, the genotype
was excluded from analysis. The minor allele frequency (MAF) was also determined and compared to
the MAF in the literature (Table 2).
Associations of the SNPs with the endpoints were tested in the dominant model; heterozygous
variant (HT) and homozygous variant (HM) versus wildtype (WT), or the recessive model; and HM
versus HT and WT. Prior research was reviewed to determine if the variant affected the SNP in
a recessive or dominant manner. COMT 616-367C>T and 1947 G>A were tested in the dominant
model [4,15]. COMT 615+310 C>T was tested using the recessive model [4]. For both the dominant
and recessive models, the chi-squared test or Fisher’s exact test was used, depending on the cell counts
of the contingency tables. When the cell count in any of the tables was less than 10, Fisher’s exact test
was used.
Univariable associations of AKI with COMT polymorphisms p < 0.1 were considered for
multivariable logistic regression analysis together with baseline variables such as age, gender, and
cisplatin dosage, if possible. When Fishers’ exact test was used, no multivariable analysis was
performed due to the large influence of chance on the outcome.
3. Results
3.1. Patients
A total of 551 patients, with different malignancies, were included in this study. All genotypes
were in Hardy–Weinberg equilibrium (Table 2). Baseline characteristics of these patients are depicted
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in Table 3. None of the included patients had renal dysfunction at baseline. Compared with baseline,
median increase in plasma creatinine values was 10 µmol/L (interquartile range (IQR) 3–21 µmol/L)
during treatment. AKI grade 3 occurred in 27 patients (5%).
Table 3. Patient characteristics.
Characteristics Controls, n = 524 AKI grade 3 (n = 27)
Gender (n)
- Male 310 (59%) 20 (74%)
- Female 214 (39%) 7 (26%)
Age (years)
- Median (IQR) 57 (45–65) 62 (57–66)
Primary tumour (n)
- Pulmonary 139 (27%) 4 (15%)
- Gastrointestinal 121 (23%) 2 (7%)
- Testicular 71 (14%) 1 (4%)
- Gynaecological 66 (13%) 3 (11%)
- Head / neck 56 (11%) 14 (52%)
- Other 71 (14%) 3 (11%)
Baseline plasma creatinine concentrations
- Median (IQR) (µmol/L) 69 (59–81) 70 (64-77)
- Median (IQR) (mg/dL) 0.78 (0.67–0.92) 0.79 (0.72–0.87)
eGFR
- Median CKD-EPI (IQR) (mL/min) 98 (85–106) 95 (81–99)
Peak creatinine concentrations
- Median (IQR) (µmol/L) 81 (69–96) 131 (117–166)
- Median (IQR) (mg/dL) 0.92 (0.78–1.09) 1.48 (1.32–1.88)
eGFR
- Median CKD-EPI (IQR) (mL/min) 87 (70–99) 44 (35–51)
Dehydration as potential cause of AKI (n) N/A 25 (93%)
Irreversible creatinine augmentation (n) N/A 4 (15%)
Cisplatin dosage (n)
- <50 mg/m2 119 (23%) 10 (37%)
- 50–79 mg/m2 298 (57%) 12 (44%)
- ≥ 80 mg/m2 107 (20%) 5 (19%)
3.2. Effect of COMT SNPs on Nephrotoxicity
All tested associations between the SNPs and AKI grade 3 are displayed in Table 4. COMT
c.616-367C>T was significantly associated with less AKI grade 3 when performing a dominant analysis
(CT + TT vs. CC, p = 0.014, odds ratio (OR) 0.201 95% confidence interval (CI) (0.047–0.861)). Age
≥65 years was univariably associated with the incidence of AKI grade 3 (p = 0.025, OR 2.464, 95% CI
(1.095–5.542)) but dosage ≥80 mg/m2 and gender were not (Table 4). Association between the SNPs
and ∆estimated glomerular filtration rate (eGFR) was also tested (Supplementary Table S1).
Upon analysis of patient files of the patients with AKI grade 3, the creatinine concentration did not
return to baseline in four out of 27 patients. In 25 out of 27 patients that had AKI grade 3, dehydration
could not be excluded as a potential cause of AKI (Table 3).
COMT 1947G>A and COMT c.615 + 310C>T were not significantly associated with AKI.
Table 4. Associations of AKI grade 3 with SNPs and confounders and the number of AKI grade 3 per
patient group.
Endpoint Factor Groups (AKI grade 3/patients)
Univariable
OR
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AKI grade 3 
COMT (615+310C>T)  
COMT (616-367C>T) 
COMT (1947G>A) 
Age≥65 
Dosage≥80mg/m2 
Gender 
TT (4/31) vs CC + CT (23/520)   
CT + TT (2/151) vs CC (25/400) 
GA + AA (21/434) vs GG (6/117)  
≥65 (10/111) vs <65 (17/440) 
≥80 (7/112) vs <80 (20/439) 
Male (20/310) vs Female (7/221) 
3.201 (1.034-9.912)  
0.201 (0.047-0.861) 
1.063 (0.419-2.697) 
2.464 (1.095-5.542) 
1.397 (0.575-3.391) 
1.972 (0.820-4.746) 
0.058* 
0.014* 
0.814* 
0.025 
0.464* 
0.159* 
*Fisher’s exact test,  
ɣ 
Odds ratio of ‘Groups’. 
Upon analysis of patient files of the patients with AKI grade 3, the creatinine concentration did 
not return to baseline in four out of 27 patients. In 25 out of 27 patients that had AKI grade 3, 
dehydration could not be excluded as a potential cause of AKI (Table 3).  
COMT 1947G>A and COMT c.615 + 310C>T were not significantly associated with AKI.  
None of the associations could be tested multivariably as all genetic associations were tested 
using Fishers’ exact test. 
4. Discussion 
This was the first study in which the association of COMT SNPs with cisplatin-induced AKI was 
assessed. Although we found a significant association between COMT c.616-367 C>T and cisplatin-
induced AKI grade 3, we cannot rule out that this result was affected by dehydration, which we could 
not exclude in 25 of 27 patients. Insufficient data regarding hydration state was available as the data 
collection was performed retrospectively. The association of dehydration could, therefore, not be 
statistically tested in this cohort. However, as 25 patients with AKI grade 3 were potentially 
dehydrated according to their patient files, this could indicate that dehydration is a more important 
factor in the development of AKI than COMT SNPs.  
Despite this large cohort of patients treated with cisplatin, the occurrence of AKI grade 3 was 
insufficient to perform the chi-square test, and, therefore, did not comply with the requirements for 
multivariable analysis as stated in the methods section. An analysis using any AKI was not performed 
as this would not be clinically relevant. The occurrence of AKI grade 1 or 2 would not lead to dose 
reduction or treatment delay. As all but four patients with AKI grade 3 ultimately had complete 
recovered renal function, the underlying pathophysiological mechanism seems to point at a prerenal 
cause of AKI, which was most likely caused by dehydration. Moreover, based on the physiological 
mechanism, one would expect that patients harboring this polymorphism would be at more risk of 
developing AKI grade 3, rather than at reduced risk as we found. Additionally, the other investigated 
SNPs in COMT were not significantly associated with AKI grade 3. These data do, therefore, not 
provide a rationale for pre-emptive genotyping of COMT. 
Of the patients who developed AKI grade 3, 52% were diagnosed with head or neck tumors 
(Table 3). Thirteen out of these 14 patients with this tumor type were treated by chemoradiotherapy 
(including cisplatin) which caused mucositis in up to 97% of the patients [16]. Oral mucositis can 
cause severe pain, which complicates drinking and is, therefore, a causal factor for dehydration. The 
fact that head and neck tumors are overrepresented in this group underlines the plausibility that AKI 
grade 3 in most of the patients was caused by dehydration. The standard use of prehydration and 
posthydration schemes show that many efforts are being made to prevent cisplatin-induced 
nephrotoxicity. Nonetheless, these efforts do not guarantee that the kidney function will remain 
stable during treatment. 
The size of the studied patient population, which was prospectively identified, allowed us to 
study a relatively large number of patients with cisplatin-induced AKI. However, the retrospective 
collection of clinical data comes with several limitations. As we studied plasma creatinine 
concentrations, exact pathophysiological mechanisms of kidney injury could not be retrieved. In most 
patients, dehydration had to be determined by anamnestic information and (the time of) recovery 
after rehydration. Data on possible confounders such as fluid intake, co-medication, diarrhea, and 
nausea were not available and, due to the small sample size, could not be adjusted for in a 
(95% CI) p-value
AKI grade 3
COMT (615+310C>T) TT (4/31) vs CC + CT (23/520) 3.201 (1.034-9.912) 0.058 *
COMT (616-367C>T) CT + TT (2/151) vs CC (25/400) 0.201 (0.047-0.861) 0.014 *
COMT (1947G>A) GA + AA (21/434) vs GG (6/117) 1.063 (0.419-2.697) 0.814 *
Age ≥ 65 ≥65 (10/111) vs <65 (17/440) 2.464 (1.095-5.542) 0.025
Dosage ≥ 80mg/m2 ≥80 (7/112) vs <80 (20/439) 1.397 (0.575-3.391) 0.464 *
Gender Male (20/310) vs Female (7/221) 1.972 (0.820-4.746) 0.159 *
* Fisher’s exact test,
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AKI grade 3 
COMT (615+310C>T)  
COMT (616-367C>T) 
COMT (1947G>A) 
Age≥65 
Dosage≥80mg/m2 
Gender 
TT (4/31) vs CC + CT (23/520)   
CT + TT (2/151) vs CC (25/400) 
GA + AA (21/434) vs GG (6/117)  
≥65 (10/111) vs <65 (17/440) 
≥80 (7/112) vs <80 (20/439) 
Male (20/310) vs Female (7/221) 
3.201 (1.034-9.912)  
0.201 (0.047-0.861) 
1.063 (0.419-2.697) 
2.464 (1.095-5.542) 
1.397 (0.575-3.391) 
1.972 (0.820-4.746) 
0.058* 
0.014* 
0.814* 
0.025 
0.464* 
0.159* 
*Fisher’s exact test,  
ɣ 
Odds ratio of ‘Groups’. 
Upon analysis of patient files of the patients with AKI grade 3, the creatinine concentration did 
not return to baseline in four out of 27 patients. In 25 out of 27 patients that had AKI grade 3, 
dehydration could not be excluded as a potential cause of AKI (Table 3).  
COMT 1947G>A and COMT c.615 + 310C>T were not significantly associated with AKI.  
None of the associati ns could b  teste multivariably as all genetic associ tions were t sted 
using Fishers’ exact test. 
4. Discussion 
This was the first study in which the association of COMT SNPs with cisplatin-induced AKI was 
assessed. Although we found a significant association between COMT c.616-367 C>T and cisplatin-
induced AKI grade 3, we cannot rule out that this result was affected by dehydration, which we could 
not exclude in 25 of 27 patients. Insufficient data regarding hydrati n st te was available as the d ta 
collection was performed retrospectively. The association of dehydration could, therefore, not be 
statistically tested in this cohort. However, as 25 patients with AKI grade 3 were potentially 
dehydrated according to their patient fil s, thi  could indicate that dehydration is a more important 
factor in the development of AKI tha  COMT SNPs.  
Despite this large cohort of patients treated with cisplatin, the occurrence of AKI grade 3 was 
insufficient to perform the chi-square test, and, therefore, did not comply with the requirements for 
multivariable analysis as stat d in the methods section. An analysis using any AKI was not performed 
as this would not be clinically releva t. The occurrence of AKI grade 1 or 2 would not lead to dose 
reduction or treatment delay. As all but four patients with AKI grade 3 ultimately had complete 
recovered renal function, the underlying pathophysiological mechanism seems to point at a prerenal 
cause of AKI, which was most likely c used by dehydration. Moreover, based on the physiological 
mechanism, one would expect that patients harboring this polymorphism would be at more risk of 
developing AKI grade 3, rather than at reduced risk as we found. Additionally, the other investigated 
SNPs in COMT were not significantly associated with AKI grade 3. These data do, therefore, not 
provide a rationale for pre-emptive genotyping of COMT. 
Of the patients who d veloped AKI grade 3, 52% were diagnosed with h ad or neck tumors 
(Table 3). Thirteen out of these 14 patients with this tumor type were treated by chemoradiotherapy 
(including cisplatin) which caused mucositis in up to 97% of the patients [16]. Oral mucositis can 
cause severe pain, which complicates drinking and is, therefore, a causal factor for dehydration. The 
fact that head and neck tumors are overrepresented in this group underlines the plausibility that AKI 
grade 3 in most of the patients was caused by dehydration. The standard use of prehydration and 
posthydration schemes show that many efforts are being made to prevent cisplatin-induced 
nephrotoxicity. Nonetheless, these efforts do not guarantee that the kidney function will remain 
stable during treatment. 
The size of the studied patient population, which was prospectively identified, allowed us to 
study a relatively large number of patients with cisplatin-induced AKI. However, the retrospective 
collection of clinical data comes with several limitations. As we studied plasma creatinine 
concentrations, exact pathophysiological mechanisms of kidney injury could not be retrieved. In most 
patients, dehydration had to be determined by anamnestic information and (the time of) recovery 
after rehydration. Data on possible confounders such as fluid intake, co-medication, diarrhea, and 
nausea were not available and, due to the small sample size, could not be adjusted for in a 
Odds ratio of ‘Groups’.
Genes 2020, 11, 358 5 of 7
None of the associations could be tested multivariably as all genetic associations were tested using
Fishers’ exact test.
4. Discussion
This was the first study in which the association of COMT SNPs with cisplatin-induced AKI
was assessed. Although we found a significant association between COMT c.616-367 C>T and
cisplatin-induced AKI grade 3, we cannot rule out that this result was affected by dehydration,
which we could not exclude in 25 of 27 patients. Insufficient data regarding hydration state was
available as the data collection was performed retrospectively. The association of dehydration could,
therefore, not be statistically tested in this cohort. However, as 25 patients with AKI grade 3 were
potentially dehydrated according to their patient files, this could indicate that dehydration is a more
important factor in the development of AKI than COMT SNPs.
Despite this large cohort of patients treated with cisplatin, the occurrence of AKI grade 3 was
insufficient to perform the chi-square test, and, therefore, did not comply with the requirements for
multivariable analysis as stated in the methods section. An analysis using any AKI was not performed
as this would not be clinically relevant. The occurrence of AKI grade 1 or 2 would not lead to dose
reduction or treatment delay. As all but four patients with AKI grade 3 ultimately had complete
recovered renal function, the underlying pathophysiological mechanism seems to point at a prerenal
cause of AKI, which was most likely caused by dehydration. Moreover, based on the physiological
mechanism, one would expect that patients harboring this polymorphism would be at more risk of
developing AKI grade 3, rather than at reduced risk as we found. Additionally, the other investigated
SNPs in COMT were not significantly associated with AKI grade 3. These data do, therefore, not
provide a rationale for pre-emptive genotyping of COMT.
Of the patients who developed AKI grade 3, 52% were diagnosed with head or neck tumors
(Table 3). Thirteen out of these 14 patients with this tumor type were treated by chemoradiotherapy
(including cisplatin) which caused mucositis in up to 97% of the patients [16]. Oral mucositis can
cause severe pain, which complicates drinking and is, therefore, a causal factor for dehydration.
The fact that head and neck tumors are overrepresented in this group underlines the plausibility that
AKI grade 3 in most of the patients was caused by dehydration. The standard use of prehydration
and posthydration schemes show that many efforts are being made to prevent cisplatin-induced
nephrotoxicity. Nonetheless, these efforts do not guarantee that the kidney function will remain stable
during treatment.
The size of the studied patient population, which was prospectively identified, allowed us to study
a relatively large number of patients with cisplatin-induced AKI. However, the retrospective collection
of clinical data comes with several limitations. As we studied plasma creatinine concentrations, exact
pathophysiological mechanisms of kidney injury could not be retrieved. In most patients, dehydration
had to be determined by anamnestic information and (the time of) recovery after rehydration. Data
on possible confounders such as fluid intake, co-medication, diarrhea, and nausea were not available
and, due to the small sample size, could not be adjusted for in a multivariate analysis. However, these
factors as a possible cause of AKI must be taken into account during cisplatin treatment. Other causes
of AKI grade 3 have not been investigated regularly and urinalysis was performed only in a minority
of patients. Moreover, there was large heterogeneity in the interval between blood draws, since these
were only regularly scheduled in advance of each chemotherapy cycle and additional blood draws
were executed based on clinical judgement of symptoms and hydration status. Therefore, temporary
and asymptomatic elevations in plasma creatinine might have been missed in this study.
Cisplatin-induced nephrotoxicity is currently mostly prevented with hyperhydration, magnesium
supplementation or mannitol-induced forced diuresis, whereas none of these measures will guarantee
that kidney function will remain stable [17]. Amifostine and cimetidine exert serious side effects and
offer only a partial degree of nephroprotection against cisplatin nephrotoxicity [18–21]. Erlotinib has
been suggested to have a beneficial effect on cisplatin nephrotoxicity by competitively inhibiting the
Genes 2020, 11, 358 6 of 7
OCT2 enzyme. This has not been validated yet [22]. So far, no perfect prevention is present, which
renders the search for predictors of important dose limited toxicities of cisplatin still relevant.
In conclusion, we found that COMT c.616-367 C>T is significantly protectively associated with
the incidence of AKI grade 3 during cisplatin treatment. Despite the considerable size of this cohort,
there was insufficient power and lack of data on hydration state to investigate the extent in which
possible confounders such as dehydration affected this result. This study did not provide a rationale
for pre-emptive genotyping of COMT SNPs to predict AKI in patients treated with cisplatin. The
retrospective nature of this study necessitates prospective validation.
Supplementary Materials: The following are available online at http://www.mdpi.com/2073-4425/11/4/358/s1,
Table S1: Associations of ∆eGFR with SNPs and confounders.
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